Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Victoria Patterson(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Benjamin L. Lampson(Harvard University), Josie Montegaard(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Jessica Lowney(Dana-Farber Cancer Institute), Samantha Pazienza(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Zixu Wang(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Matthew Weinstock(Beth Israel Deaconess Medical Center)
Cited by 102
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k